MedTrace Logo

Effect of Anti-IgE in Chronic Urticaria

NCT00130234 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2008-05-07

No results posted yet for this study

Summary

This study is being done to find out if a drug called Xolair (omalizumab), an anti-IgE antibody, is safe and effective for people with chronic urticaria (hives) with persistent symptoms in spite of taking antihistamines.

Conditions

  • Urticaria

Interventions

DRUG

Xolair® (Omalizumab)

Sponsors & Collaborators

Principal Investigators

  • Sarbjit Saini, M.D. · Johns Hopkins Asthma and Allergy Center, Division of Allergy and Clinical Immunology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-30
Primary Completion
2007-09-30
Completion
2007-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00130234 on ClinicalTrials.gov